The missing conception for integrating pre-clinical results in clinical practice underlines missing communication-based therapeutic paradigms provided by an evolution-adjusted tumor pathophysiology and implies an unjustified hesitant introduction of master modulators, including PPARα/γ agonists, like pioglitazone in tumor therapy (Table 1). Here, PPARA is linked to neoplasm.